Search results for "pair [nucleon]"

showing 10 items of 68 documents

The MRN complex is transcriptionally regulated by MYCN during neural cell proliferation to control replication stress

2015

The MRE11/RAD50/NBS1 (MRN) complex is a major sensor of DNA double strand breaks, whose role in controlling faithful DNA replication and preventing replication stress is also emerging. Inactivation of the MRN complex invariably leads to developmental and/or degenerative neuronal defects, the pathogenesis of which still remains poorly understood. In particular, NBS1 gene mutations are associated with microcephaly and strongly impaired cerebellar development, both in humans and in the mouse model. These phenotypes strikingly overlap those induced by inactivation of MYCN, an essential promoter of the expansion of neuronal stem and progenitor cells, suggesting that MYCN and the MRN complex migh…

0301 basic medicineDNA ReplicationTranscription GeneticDNA damageDNA repairDNA-Binding ProteinCell Cycle ProteinsBiology03 medical and health sciencesMRE11 Homologue ProteinCell Cycle ProteinStrand-Break Repair; N-Myc; Dna-Replication; Human Neuroblastoma; Feingold-Syndrome; C-Myc; Mre11-Rad50-Nbs1 Complex; Targeted Disruption; Genomic Instability; Embryonic LethalityHumansProgenitor cellMolecular BiologyneoplasmsCells CulturedNuclear ProteinCell ProliferationGeneticsNeuronsOncogene ProteinsOriginal PaperMRE11 Homologue ProteinN-Myc Proto-Oncogene ProteinCell growthDNA Repair EnzymeDNA replicationOncogene ProteinNuclear ProteinsCell BiologyNeuronCell biologyAcid Anhydride HydrolasesDNA-Binding Proteins030104 developmental biologyDNA Repair EnzymesMRN complexGene Expression RegulationRad50HumanCell Death and Differentiation
researchProduct

Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?

2018

Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7, and oral TMZ 150 to 200 mg/m

0301 basic medicineOncologyMaleLung NeoplasmsDNA Mutational AnalysisPoly (ADP-Ribose) Polymerase-1Placebos0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsPromoter Regions GeneticDNA Modification MethylasesAged 80 and overStandard treatmentNuclear ProteinsMiddle AgedNeoplastic Cells CirculatingImmunohistochemistryhumanitiesEditorialOncology030220 oncology & carcinogenesisFemaleNon small cellAdultmedicine.medical_specialtyMEDLINEAggressive disease03 medical and health sciencesText miningDouble-Blind MethodInternal medicinemedicineBiomarkers TumorTemozolomideHumansLung cancerneoplasmsAntineoplastic Agents AlkylatingAgedbusiness.industryTumor Suppressor ProteinsDNA Methylationmedicine.diseaseSmall Cell Lung Carcinomarespiratory tract diseases030104 developmental biologyDNA Repair EnzymesBenzimidazolesPersonalized medicinebusiness
researchProduct

Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Sy…

2021

Abstract Purpose To determine impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy (BSO) on gynecological cancer incidence and death in heterozygotes of pathogenic MMR ( path_MMR ) variants. Methods The Prospective Lynch Syndrome Database was used to investigate the effects of gynecological risk-reducing surgery (RRS) at different ages. Results Risk-reducing hysterectomy at 25 years of age prevents endometrial cancer before 50 years in 15%, 18%, 13%, and 0% of path_MLH1 , path_MSH2 , path_MSH6 , and path_PMS2 heterozygotes and death in 2%, 2%, 1%, and 0%, respectively. Risk-reducing BSO at 25 years of age prevents ovarian cancer before 50 years in 6%, 11%, 2%, and 0% and…

0301 basic medicinemedicine.medical_treatmentDNA Mismatch RepairGynecologic surgery0302 clinical medicineMalalties hereditàriesProspective StudiesProspective cohort studyGenetics (clinical)Mismatch Repair Endonuclease PMS2Incidence (epidemiology)Middle Aged16. Peace & justiceLynch syndrome3. Good health030220 oncology & carcinogenesisFemalesyöpätauditMutL Protein Homolog 1Genetic diseasesHeterozygotemedicine.medical_specialtySalpingo-oophorectomyCirurgia ginecològicaHysterectomyArticle03 medical and health sciencesCàncer colorectalCAPP2medicineHumansLynchin oireyhtymäGynecologyperinnölliset tauditHysterectomyHEREDITARY COLORECTAL-CANCERbusiness.industryEndometrial cancerCancermedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisColorectal cancerASPIRIN030104 developmental biologyClinical researchLynch syndrome3121 General medicine internal medicine and other clinical medicinekohdunpoisto3111 BiomedicineOvarian cancerbusiness
researchProduct

Occupational exposure to metal-rich particulate matter modifies the expression of repair genes in foundry workers

2021

Foundry workers are exposed to numerous occupational health hazards, which may result in increased risk of cancer, respiratory disease, and other diseases. Oxidative stress is known to be involved in the pathogenesis of such diseases. The present study aimed to investigate the association between multiple occupational exposures in foundry workers and expression of deoxyribonucleic acid (DNA) repair genes as a biomarker of oxidative DNA damage. The study sample comprised 17 foundry workers and 27 matched control subjects. Expression of 8-oxoguanine DNA glycosylase-1 (OGG1), inosine triphosphate pyrophosphate (ITPA), and MutT homolog 1 (MTH1) in peripheral blood was examined using the real-t…

AdultMaleDNA repairThreshold limit valueHealth Toxicology and MutagenesisIran010501 environmental sciencesToxicologymedicine.disease_cause01 natural sciencesDNA Glycosylaseslaw.invention03 medical and health sciencesElectromagnetic FieldslawMetals HeavyOccupational ExposureHumansMedicinePyrophosphatasesGenePolymerase chain reaction030304 developmental biology0105 earth and related environmental sciences0303 health sciencesbusiness.industryPublic Health Environmental and Occupational HealthMiddle AgedPhosphoric Monoester HydrolasesOxidative StressDNA Repair EnzymesCase-Control StudiesMetallurgyImmunologyToxicityBiomarker (medicine)Particulate MatterITPAbusinessBiomarkersOxidative stressDNA DamageToxicology and Industrial Health
researchProduct

Chemoradiotherapy of Newly Diagnosed Glioblastoma With Intensified Temozolomide

2009

Purpose To evaluate the toxicity and efficacy of chemoradiotherapy with temozolomide (TMZ) administered in an intensified 1-week on/1-week off schedule plus indomethacin in patients with newly diagnosed glioblastoma. Patients and Methods A total of 41 adult patients (median Karnofsky performance status, 90%; median age, 56 years) were treated with preirradiation TMZ at 150 mg/m 2 (1 week on/1 week off), involved-field radiotherapy combined with concomitant low-dose TMZ (50 mg/m 2 ), maintenance TMZ starting at 150 mg/m 2 using a 1-week on/1-week off schedule, plus maintenance indomethacin (25 mg twice daily). Results The median follow-up interval was 21.7 months. Grade 4 hematologic toxicit…

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentIndomethacinDisease-Free SurvivalDrug Administration ScheduleGermanyInternal medicineConfidence IntervalsTemozolomidemedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesKarnofsky Performance StatusAntineoplastic Agents AlkylatingDNA Modification MethylasesSurvival rateAgedChemotherapyRadiationTemozolomideBrain Neoplasmsbusiness.industryTumor Suppressor ProteinsAnti-Inflammatory Agents Non-SteroidalDNA MethylationMiddle AgedCombined Modality TherapyConfidence intervalSurgeryDacarbazineSurvival RateRegimenDNA Repair EnzymesOncologyConcomitantToxicityFemaleGlioblastomabusinessChemoradiotherapyFollow-Up Studiesmedicine.drugInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.

2011

The NOA-05 multicenter trial was performed to analyze the efficacy of primary chemotherapy with procarbazine and lomustine (PC) in patients with gliomatosis cerebri (GC) and to define clinical, imaging, and molecular factors influencing outcome.Thirty-five patients with previously untreated GC were treated with up to six 56-day courses of 110mg/m(2) lomustine on day 1 and 60mg/m(2) procarbazine on days 8 to 21. The primary endpoint was the rate of patients without therapy failure (defined as progressive disease, death from any cause, or termination of PC therapy before the end of course 4) at 8 months after the beginning of PC chemotherapy.The failure-free survival rate at 8 months was 50.3…

AdultMalemedicine.medical_specialtyEndpoint DeterminationGliomatosis cerebriAntineoplastic AgentsGene mutationProcarbazineGastroenterologyDisease-Free SurvivalLomustineInternal medicineMulticenter trialAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansProspective StudiesKarnofsky Performance StatusSurvival rateDNA Modification MethylasesAgedbusiness.industryTumor Suppressor ProteinsHazard ratioBrainLomustineMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyMagnetic Resonance ImagingNeoplasms NeuroepithelialSurvival AnalysisSurgeryDNA Repair EnzymesTreatment OutcomeNeurologyProcarbazineSample SizeDisease ProgressionFemaleNeurology (clinical)businessProgressive diseasemedicine.drugAnnals of neurology
researchProduct

Activity and safety of temozolomide in advanced adrenocortical carcinoma patients

2019

Objective Temozolomide has shown a significant anti-proliferative activity on adrenocortical cancer (ACC) cells in vitro. Design On the basis of these results the drug was prescribed as second/third line in advanced metastatic ACC patients in four referral centers in Italy. Methods We retrospectively collected anagraphic, clinical and pathological data of patients with advanced ACC with disease progression to standard chemotherapy plus mitotane who were treated with temozolomide at the dose of 200 mg/m2/die given for 5 consecutive days every 28 days. The primary endpoint was the disease control rate, defined as objective response or disease stabilization after 3 months. Secondary endpoints…

AdultOncologymedicine.medical_specialtytemozolomide adrenocortical carcinomaDisease ResponseSettore MED/06 - Oncologia MedicaEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineEndocrinologyStable DiseaseInternal medicineAdrenocortical CarcinomaTemozolomideClinical endpointHumansMedicineAdrenocortical carcinomaMitotaneDNA Modification MethylasesAgedRetrospective StudiesChemotherapyTemozolomidebusiness.industryTumor Suppressor ProteinsRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseDNA Repair EnzymesEndocrinology030220 oncology & carcinogenesisbusinessmedicine.drug
researchProduct

Repair of oxidatively generated DNA damage in Cockayne syndrome

2013

Defects in the repair of endogenously (especially oxidatively) generated DNA modifications and the resulting genetic instability can potentially explain the clinical symptoms of Cockayne syndrome (CS), a hereditary disease characterized by developmental defects and neurological degeneration. In this review, we describe the evidence for the involvement of CSA and CSB proteins, which are mutated in most of the CS patients, in the repair and processing of DNA damage induced by reactive oxygen species and the implications for the induction of cell death and mutations. Taken together, the data demonstrate that CSA and CSB, in addition to their established role in transcription-coupled nucleotide…

AgingDNA RepairTranscription GeneticDNA damageDNA repairBiologymedicine.disease_causeCockayne syndromemedicineAnimalsHumansCockayne SyndromePoly-ADP-Ribose Binding ProteinsMutationDNA HelicasesBase excision repairmedicine.diseaseMolecular biologyCell biologyDNA Repair EnzymesMitochondrial DNA repairMutationDNA mismatch repairOxidation-ReductionDNA DamageTranscription FactorsDevelopmental BiologyNucleotide excision repairMechanisms of Ageing and Development
researchProduct

MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents

2007

O(6)-methylguanine-DNA methyltransferase (MGMT) plays a crucial role in the defense against alkylating agents that generate, among other lesions, O(6)-alkylguanine in DNA (collectively termed O(6)-alkylating agents [O(6)AA]). The defense is highly important, since O(6)AA are common environmental carcinogens, are formed endogenously during normal cellular metabolism and possibly inflammation, and are being used in cancer therapy. O(6)AA induced DNA damage is subject to repair, which is executed by MGMT, AlkB homologous proteins (ABH) and base excision repair (BER). Although this review focuses on MGMT, the mechanism of repair by ABH and BER will also be discussed. Experimental systems, in wh…

Alkylating AgentsMethyltransferaseAlkylationDNA RepairDNA repairDNA damageGene ExpressionApoptosisIn Vitro TechniquesBiologyDNA Mismatch RepairModels BiologicalBiochemistryNecrosisO(6)-Methylguanine-DNA MethyltransferaseNeoplasmsAnimalsHumansDNA Modification MethylasesneoplasmsMolecular BiologyCarcinogenChromosome AberrationsGeneticsTumor Suppressor ProteinsO-6-methylguanine-DNA methyltransferaseDNACell BiologyBase excision repairdigestive system diseasesDNA Repair EnzymesMutationCancer researchDNA mismatch repairSister Chromatid ExchangeDNA DamageAlkyltransferaseDNA Repair
researchProduct

Pair-bonding in birds and the active role of females: a critical review of the empirical evidence.

2000

Over the recent years the role of females in maintaining or breaking the pair-bond in socially monogamous birds has received growing attention. Here, we review the overall evidence for a direct and predominant role of female behaviour in initiating or preventing divorce and its relevance for the understanding of both interspecific and intraspecific variation in divorce rate in monogamous bird species. The evidence is so far limited to a few species. We discuss the relevance of some alternative explanations and confounding factors. We conclude that the possible predominance of females in both initiating divorce or limiting its occurrence deserves further consideration. Future studies should …

Behavioral NeuroscienceFuture studiesConfoundingRelevance (law)Animal Science and ZoologyExtra-pair copulationGeneral MedicineInterspecific competitionEmpirical evidencePsychologySocial relationIntraspecific competitionDevelopmental psychologyBehavioural processes
researchProduct